The threat of antimicrobial resistance (AMR), rendering current antibiotics, antifungals and antivirals obsolete is an urgent global issue.
Biotaspheric recognises the urgency and necessity for new innovative anti-infective technologies and is at the forefront of the changing commercial proposition for AMR and the evolving regulatory market. Biotaspheric can identify promising technologies and accelerate innovative anti-infectives via their unique offering:
The Biotaspheric team comprises global specialists across each key area of development, from investment, pre-clinical and clinical development, through to market access and reimbursement, providing a breadth of robust support and knowledge
Our team of experts understands the nuances of the anti-infective market. With decades of academic and industry experience, we can identify the optimum indications for development and provide guidance on product life cycle management and responsible use of new treatments, helping to limit further resistance development.
Biotaspheric offers a holistic approach to development through our network of recognised alliances across the industry.
Biotaspheric’s unique combination of network, knowledge and expertise helps to secure funding and investment for product development